Biopharmaceutical Analysis

Paul Van Tilborg is director of analytical sciences at Ardena.

Articles

A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.

Phase-appropriate Analytical Methodology

Mark Rogers, PhD, mark.rogers@sgs.com, is the global scientific director for the SGS Health Science Drug Development group. He  has been with SGS for nearly 8 years since joining the company via an acquisition (M-Scan) in 2010. Rogers received his PhD in analytical chemistry from Westminster University in 1985 and has over 35 peer-reviewed publications, including Nature, and one patent. His post-doctoral work, at Imperial College, London, was followed by a lectureship in the endocrinology department at St. Mary’s hospital specializing in diabetes. Rogers then went on to join M-Scan, USA in 1990 where he remained as vice-president until its acquisition by SGS. Since joining SGS he has had several roles including, head of North American Biologics, vice-president of SGS USA, and today, he is the Global Scientific director for the SGS Health Science Drug Development group.

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The Marriage of RNA and Mass Spectrometry

Kinjal Sankhe is recognized as a technical expert with growing scientific contributions in vaccine research and department. She has experience in various aspects of clinical trials management. Sankhe holds a bachelor’s degree in veterinary medicine and animal husbandry from Bombay Veterinary College, Mumbai, India, and a master’s degree in biomedical science from Northeastern University, Boston, MA. She can be contacted at 

Big data is a natural for pharmaceutical industry players that have not already embraced it.

Big Pharma Meets Big Data

Jon Bardsley is market development manager, Pharma & BioPharma, at Thermo Fisher Scientific.

Advanced LC technologies can streamline the review process for LC equipment maintenance.

Tools and Technologies for Robust Method Lifecycle Management in Liquid Chromatography

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Affinity chromatography resins must perform well under mild elution conditions yet withstand robust cleaning and sanitization protocols.

Choosing the Right Resins for Viral Vector Affinity Chromatography

Feliza Mirasol is the science editor for 

Biologic drug development requires relevant bioassays to measure and help predict cellular response.

Complex Analytical Workflows Increasingly Require Robust Bioassays

The launch of Discovery Life Sciences’ new Proteomic Services Division offers a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis.

Discovery Life Sciences Now Offers Large-Scale Proteomic Services

Tareq Jaber, tareq.jaber@crl.com, is associate director at Charles River Laboratories.

Anja Tessarz, Anja.Tessarz@crl.com, is associate director RGDB, SME Viral Clearance at Charles River Laboratories.

The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.

Viral Clearance Studies: Challenges and Beyond

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Biotech Startup Raises $5.4M to Develop AI-Designed Protein Machines and Cell Factories

Hanna Jankevics Jones, PhD, is a pharmaceutical segment marketing manager at Malvern Panalytical.

Natalia Markova is principal scientist, MicroCal, Malvern Instruments.

An orthogonal approach to lipid nanoparticle analysis is recommended to optimize drug development success.

Analytical Methods